KCNT1 and epilepsy: To date, the biopharmaceutical company Praxis Precision Medicine is the only one that has disclosed an advanced discovery project for the development of small-molecule therapeutics for the treatments of KCNT1-related epilepsies [82] These efforts led to the identification of the first orally available KCNT1 inhibitor (17—vide infra) described so far, identified through extensive SAR studies enclosed in several patent applications [82,83,84].